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 Abstract 
In the Sudan, as in many other countries, the emerging drug resistance of 
Mycobacterium tuberculosis is causing a major public health threat. 
Isolation, identification and antimicrobial sensitivity of Mycobacterium 
tuberculosis was the aim of this study. Three hundred and twenty nine 
sputum samples were collected from suspected pulmonary tuberculosis 
patients at Al Shaab Teaching Hospital, Abu Anga Hospital and the National 
Health Laboratory in Khartoum State during the period from October 2005 
to December 2006. 
From the gender of the patients, it was found that males were more affecied 
than females; 238 (72.3%) males and 91 (27.7%) females. All age groups 
were affected, but with varying degrees. The age at most risk was found 
between 21 and 40 years, which comprised 213 (64.7%) patients. The 
highest infection rate according to occupation of the patients was found 
among labourers (36%) whereas lowest infection rate was found among 
unemployed people (8%). The majority of patients came to the above 
mentioned health institutions from other states. It was found that most of 
patients were from Western and Southern Sudan states, where the economic 
and health status is poor. 
Out of 329 sputum samples, 294 (89.4%) revealed Mycobacterium 
tuberculosis complex, 6 (1.8%) revealed rapidly growing mycobacteria, 10 
(3.0%) revealed growth of  Nocardia spp., 6 (1.8%) specimens were found 
contaminated and failed to isolate any acid fast bacilli from them and 13 
(4.0%) showed no growth. 
The M. tuberculosis complex isolates were identified phenotypically 
according to their microscopic, cultural and some biochemical properties. 
The phenotypic identification was confirmed genotypically, when 100 
 xi
isolates were randomely selected for detection of the insertion element 
1S6110 after PCR amplification using specific primers to the target gene 
sequence and gel electrophoreses for detection of the target size (123bp). A 
band of the typical size was observed for all the test isolates. 
Lowenstein Jensen proportion method was used to test the antimicrobial 
sensitivity of 200 isolates of Mycobacterium tuberculosis complex against 4 
drugs: isoniazid (INH), rifampicin (RIF), streptomycin (STM) and 
ethambutol (EMB). Only 67 (33.5%) isolates were sensitive to the four 
drugs. Mono-drug resistance was as follows: 35 (17.5%) isolates were 
resistant to INH, 31 (15.5%) were restraint to RIF, 43 (21.5%) were resistant 
to STM and 24 (12%) were resistant to EMB. While, the multi-drug 
resistance was as follows: 12 (6%) isolates were resistant to INH and RIF, 5 
(2.5%) were resistant to three drugs and 9 (4.5%) were resistant to the four 
drugs.  
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
 ﺃﺼﺒﺤﺕ ﻤﺸﻜﻠﺔ ﻤﻘﺎﻭﻤﺔ ﻋﺼﻴﺎﺕ ﺍﻟﺴل ، ﻜﻤﺎ ﻓﻲ ﺍﻟﻌﺩﻴﺩ ﻤﻥ ﺍﻟﺩﻭل ﺍﻻﺨﺭﻱ،ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ        
ﻫﺫﻩ ﺃﺠﺭﻴﺕ .ﺍﻟﻌﺎﻤﺔﺍﻟﺭﺌﻭﻱ ﻟﻠﻌﻘﺎﻗﻴﺭ ﺍﻟﻤﺴﺘﺨﺩﻤﺔ ﻓﻲ ﻋﻼﺝ ﺍﻟﻤﺭﺽ ﺘﺸﻜل ﺘﻬﺩﻴﺩﺍ ﺭﺌﻴﺴﻴﺎ ﻟﻠﺼﺤﺔ 
 ﺍﻟﻤﺴﺘﺨﺩﻤﺔ ﻓﻲ  ﻋﺼﻴﺎﺕ ﺍﻟﺴل ﺍﻟﺭﺌﻭﻱ ﻟﻠﻌﻘﺎﻗﻴﺭﻤﻌﺭﻓﺔ ﺨﺼﺎﺌﺹ ﻭﺤﺴﺎﺴﻴﺔﺒﻐﺭﺽ ﻋﺯل ﻭﺍﻟﺩﺭﺍﺴﺔ 
   .  ﺍﻟﻌﻼﺝ
 ﺒﺎﻟﺘﺩﺭﻥ ﺍﻟﺭﺌﻭﻱ ﻤﻥ ﻤﺴﺘﺸﻔﻰ  ﺇﺼﺎﺒﺘﻬﻡﻓﻲ ﺸﺘﺒﻪﻴ ﻤﻥ ﻤﺭﻀﻲ  ﻗﺸﻊ ﻋﻴﻨﺔ٩٢٣ ﻋﺩﺩ ﺘﻡ ﺠﻤﻊ
ﺍﻟﺨﺭﻁﻭﻡ ﺍﻟﺘﻌﻠﻴﻤﻲ ﻭﻤﺴﺘﺸﻔﻲ ﺤﻤﺩ ﺍﻟﻨﻴل ﻟﻠﺼﺩﺭ ﻭ ﺍﻟﻤﻌﻤل ﺍﻟﻘﻭﻤﻲ ﺍﻟﺼﺤﻲ ﻓﻲ ﻭﻻﻴﺔ ﺍﻟﺨﺭﻁﻭﻡ ﻓﻲ 
  .  ٦٠٠٢ ﺇﻟﻰ ﺩﻴﺴﻤﺒﺭ ٥٠٠٢ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﺃﻜﺘﻭﺒﺭ 
 ﺒﻨﺴﺒﺔ  ﺫﻜﺭ٨٣٢ ﻨﺎﺙ،ﺍﻹ ﻋﺩﺩ ﻤﻥﺍﻟﺫﻜﻭﺭ ﺃﻜﺜﺭ ﻋﺩﺩ  ﺍﻥ ﺠﺩﻭ ،ﺍﺴﺘﻨﺎﺩﺍ ﻋﻠﻲ ﺠﻨﺱ ﺍﻟﻤﺭﻀﻲ       
 ﻤﺨﺘﻠﻔﺔ،ﺔ ﻜﺎﻨﺕ ﻤﺼﺎﺒﺔ ﻭﻟﻜﻥ ﺒﺩﺭﺠﺎﺕ ﻴ ﻜل ﺍﻟﻔﺌﺎﺕ ﺍﻟﻌﻤﺭ.%٧,٧٢  ﺒﻨﺴﺒﺔﺜﻰ ﺇﻨ١٩ﻭ % ٣,٢٧
 ٣١٢ ﺴﻨﺔ ﻜﺎﻨﺕ ﺃﻜﺜﺭ ﻋﺭﻀﺔ ﻟﻺﺼﺎﺒﺔ ﻭ ﺍﻟﺘﻲ ﻜﺎﻨﺕ ﺘﺤﺘﻭﻯ ﻋﻠﻰ ٠٤-١٢ ﺒﻴﻥ ﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺭﻴﺔ
  ﺇﺼﺎﺒﺔ ﻜﺎﻨﺕ%(٦٣)  ﻋﻠﻲ ﻨﺴﺒﺔﺃ ﻭﺠﺩ ﺍﻥ ، ﻋﻠﻰ ﻤﻬﻥ ﺍﻟﻤﺭﻀﻰﻋﺘﻤﺎﺩﺍﹰ ﺍ.%٧,٤٦ﻤﺭﻴﺽ ﺒﻨﺴﺒﺔ 
ﻲ  ﻤﻌﻅﻡ ﺍﻟﻤﺭﻀ ﻜﺫﻟﻙ ﺘﺒﻴﻥ ﺍﻥ ﺍﻟﻁﺒﻘﺔ ﻏﻴﺭ ﺍﻟﻌﺎﻤﻠﺔ، ﺃﻓﺭﺍﺩﺒﻴﻥ%( ٨) ﻬﺎ ﺍﻟﻌﻤﺎﻟﻴﺔ ﻭﺍﻗﻠﻟﻁﺒﻘﺔﻓﻲ ﺍ
 ﻬﻡ ﻤﻌﻅﻤﺃﻥ ﻤﻥ ﻭﻻﻴﺎﺕ ﺃﺨﺭﻯ، ﺍﻤﻭﺩ ﻗ ﻗﺩ ﺤﻀﺭﻭﺍ ﺇﻟﻰ ﺍﻟﻤﺭﺍﻜﺯ ﺍﻟﺼﺤﻴﺔ ﺍﻟﺘﻲ ﺫﻜﺭﺕ ﺃﻋﻼﻩﺍﻟﺫﻴﻥ
  .ﺘﺭﺩﻱ ﻓﻲ ﺍﻟﻭﻀﻊ ﺍﻟﺼﺤﻲ ﻭﺍﻻﻗﺘﺼﺎﺩﻱﻟﻠ ﻭﻴﺭﺠﻊ ﺫﻟﻙﻤﻥ ﻏﺭﺏ ﻭﺠﻨﻭﺏ ﺍﻟﺴﻭﺩﺍﻥ 
 %(٤,٩٨) ٤٩٢ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﻔﻁﺭﺓ ﺍﻟﺴﻠﻴﺔ ﻤﻥ ﺃﻓﺭﺍﺩ، ﻋﺯﻟﺕ  ﻗﺸﻊﻋﻴﻨﺔ ٩٢٣ﻤﻥ ﻤﺠﻤل       
ﺒﻬﺎ  ﺕﻋﻴﻨﺎﺕ ﻭﺠﺩ%( ٠,٣ )٠١، ﺴﺭﻴﻌﺔ ﺍﻟﻨﻤﻭ ﺍﺕ ﻤﺘﻔﻁﺭﻋﺯﻟﺕ ﻤﻨﻬﺎ ﺎﺕﻋﻴﻨ%( ٨,١ ) ٦  ،ﻋﻴﻨﺔ
 ﻭﺫﻟﻙ ﻟﻡ ﻴﺘﻡ ﻋﺯل ﻋﺼﻴﺎﺕ ﻤﻘﺎﻭﻤﺔ ﻟﻠﺤﻤﺽ ﻤﻨﻬﺎ ﺎﺕﻋﻴﻨ%( ٨,١ ) ٦  ﻤﻥ ﺠﻨﺱ ﺍﻟﻨﻭﻜﺎﺭﺩﻴﺎ،ﺃﻨﻭﺍﻉ
  .ﻲ ﻨﻤﻭ ﻤﻴﻜﺭﻭﺒﺃﻱ ﺘﻌﻁﻟﻡ ﻋﻴﻨﺔ % (٠,٤) ٣١ ، ﻬﺎﻟﺘﻠﻭﺜ
iiix 
ﺔ، ﻴﺭﺠﻬ ﻋﻠﻰ ﺨﺼﺎﺌﺼﻬﺎ ﺍﻟﻤ ﻋﺯﻻﺕ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﻔﻁﺭﺓ ﺍﻟﺴﻠﻴﺔ ﺍﻋﺘﻤﺎﺩﺍﹰ ﻋﻠﻰﺘﻌﺭﻑﺍﻟﺘﻡ       
ﻤﻥ ( ٠٠١)  ﻫﺫﺍ ﺍﻟﺘﻌﺭﻴﻑ ﺒﻭﺍﺴﻁﺔ ﺍﻟﺨﺼﺎﺌﺹ ﺍﻟﺠﻴﻨﻴﺔ ﻟﻤﺎﺌﺔﺘﻡ ﺘﺄﻜﻴﺩﺍﻟﻤﺯﺭﻋﻴﺔ، ﻭ ﺍﻟﻜﻴﻤﻭﺤﻴﺎﺘﻴﺔ ﻭ 
 ﺍﺨﺘﺒﺎﺭ  ﺒﻭﺍﺴﻁﺔ(0116S1 )ﺍﻟﺨﺎﺹ ﻟﻠﺘﻌﺭﻑ ﻋﻠﻰ ﺍﻟﺤﻴﻥ ﻙﺍﻟﻌﺯﻻﺕ ﺍﻟﺘﻲ ﺍﺨﺘﻴﺭﺕ ﻋﺸﻭﺍﺌﻴﺎ ﻭﺫﻟ
 ل ﺍﻥ ﻜﻫﻲ  ﺍﻟﻨﺘﻴﺠﺔﻭﻜﺎﻨﺕ ﻟﻠﺠﻴﻥﻭ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﺎﺩﺌﺎﺕ ﺨﺎﺼﺔ ﻴﺭﻴﺯﻯ ﻴﻤﺍﻟﺒﻭﻟﺍﻟﺴﻠﺴﻠﻰ ﺍﻟﺘﻔﺎﻋل 
  .  ( ٣٢١ pb ) ﺍﻟﻤﻌﻴﻥ ﺤﺠﻡ ﺍﻟﺠﻴﻥ ﺱ ﺤﺯﻤﺔ ﻟﻬﺎ ﻨﻔﺃﻅﻬﺭﺕ %(٠٠١) ﺍﻟﻌﺯﻻﺕ
 :ﺍﻷﺭﺒﻌﺔ ﻸﺩﻭﻴﺔﻟﻤﻥ ﺍﻟﻤﺘﻔﻁﺭﺓ ﺍﻟﺴﻠﻴﺔ  ﻋﺯﻟﺔ ٠٠٢ﺘﻡ ﺇﺠﺭﺍﺀ ﺍﺨﺘﺒﺎﺭ ﺍﻟﺤﺴﺎﺴﻴﺔ ﻟﻌﺩﺩ       
ﻜﺎﻨﺕ % ٥,٣٣ ﺒﻨﺴﺒﺔ ﻋﺯﻟﺔ ٧٦ﻓﻘﻁ ﻋﺩﺩ .  ﺍﺜﺎﻤﺒﻴﻭﺘﻭلﺒﺘﻭﻤﺎﻴﺴﻥ،ﺍﺴﺘﺭ، ﺭﻴﻔﺎﻤﺒﺴﻴﻥ، ﺍﻴﺯﻭﻨﻴﺎﺯﻴﺩ
 ﺒﻨﺴﺒﺔ ﻋﺯﻟﺔ ١٣، ﺍﻴﺯﻭﻨﻴﺎﺯﻴﺩﻜﺎﻨﺕ ﻤﻘﺎﻭﻤﺔ % ٣,٧١ ﺒﻨﺴﺒﺔ ﻋﺯﻟﺔ ٥٣ ﻋﺩﺩ.ﺍﻷﺭﺒﻌﺔﺤﺴﺎﺴﺔ ﻟﻠﻌﻘﺎﻗﻴﺭ 
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INTRODUCTION 
The problem of tuberculosis has recently been compounded by the 
emergence of multi-drug resistant (MDR) tuberculosis. Factors 
contributing to recent outbreaks and continued spread of MDR tuberculosis 
include HIV infection (AIDS), inefficient control procedures and 
laboratory delays in identification and antibiotic susceptibility testing of 
Mycobacterium tuberculosis (Watterson et al., 1998). Rapid identification 
and susceptibility testing of isolates are, therefore, imperative for therapy 
selection and prevention of spread of resistant organisms (Pfaller, 1994). 
Unfortunately, due to the slow growth of M. tuberculosis, drug 
susceptibility testing of this organism has proved to be a challenge 
(Wanger and Mills, 1996). 
Over 90% of the tuberculosis cases occur in the developing countries, 
where clinical diagnosis of tuberculosis is based primarily on microscopic 
examination of smears for acid-fast bacilli and occasionally on chest X-
rays. Acid-fast bacillus smears are positive only during advanced 
tuberculosis. Moreover, smear-positive cases constitute only about 50% of 
pulmonary tuberculosis cases and the sensitivity of sputum smear 
microscopy has been reported to be between 22-80% of culture-confirmed 
tuberculosis cases (Colebunders and Bastian, 2000). One of the most 
alarming aspects of the recent increase in the incidence of tuberculosis is 
outbreaks involving drug-resistant strains of M. tuberculosis. Therefore, 
efficient and early case finding and rapid assessment of drug susceptibility 
testing of M. tuberculosis represents the main objective of current research 
worldwide (Davidson, 1987). Mycobacterial identification and 
characterization to the species level not only is of academic interest but 
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also is important because it provides useful information on the 
epidemiology and virulence of the organism, such data will be valuable for 
planning for intervention strategies. 
Multi-drug resistant tuberculosis becomes a major problem in Khartoum 
State where there is increasing evidence of MDR (WHO, 1998). 
Aims of the study 
The general objective of the present study was to determine the in vitro 
sensitivity and the occurrence of multi-drug resistant M. tuberculosis 
among smear-positive cases. The specific aims were as follows:  
     1. To evaluate the sensitivity of (ZN) stain compaired with the culture.                             
2. Isolation, Identification of Mycobacterium-like isolates by their 
phenotypic (microscopic, cultural and biochemical) and genotypic 
(PCR) properties. 
3. Determination of the sensitivity of these isolates to tuberculosis anti-
microbial drugs and to determine the level of multi-drug resistance 
among patients with pulmonary tuberculosis.  
4. To determine and correlate the epidemiological risk factors among 
the patients examined. 
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 Tuberculosis 
1.1.1 History of tuberculosis 
Tuberculosis was known in antiquity, for its ravages and could be 
recognized in lesions of bones that have survived. It is probably the first 
known example of the diseases of the vertebral column dates for the 
Neolithic period (about 5000 BC). There is evidence of bony lesions in 
Egyptian mummies and the disease may have been common in the 
predynastic period of Egypt (Florey and poole, 1970). How  ever it does 
not seem that tuberculosis of the lungs was common. In Egypt, no 
description of this form of the disease exists, but phthisis was recognized 
by the Greeks, and described in the Hippocratic writing (ca. 400 BC). 
Tuberculosis of the lungs was also mentioned in the India Rig-Veda (about 
1500 BC), and there were a number of representations of the disease 
among the primitive statuettes of the new world. The idea of tuberculosis 
as separate disease did not emerge until 1671 when Francis Sylvius (De le 
Boe) used the term tubercular minoravel majora to describe the appearance 
of lesions. The very accurate description of the macroscopic appearances 
“tuberculous lesions” was given by William Stark (1740-1770), whose 
work appeared in 1788, and by Matthew Baillie (1761-1823), who 
published his observations in 1793 (Florey and poole, 1970). In 1882, 
Robert Koch isolated the causative agent, Mycobacterium tuberculosis 
from crushed lung tubercles. Currently, M. tuberculosis is known as the 
world leading cause of death (Dye et al., 1999).  
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1.1.2 Definition 
Tuberculosis is a chronic granulomatous disease affecting man and many 
other mammals. It is an infection, which most commonly affects the lungs, 
where it is called pulmonary tuberculosis but it can also affect the central 
nervous system (meningitis), circulatory system and gastrointestinal tract 
(millary tuberculosis), genitourinary system, bones and joints where it is 
called extra-pulmonary TB (Grange, 2002). 
1.2 The Bacterium  
1.2.1 Description of Mycobacterium tuberculosis complex 
 Mycobacterium is Gram-positive straight or slightly curved rod, typically 
does not stain well with Gram’s stain due to its waxy surface. The 
organism has a cell wall which contains an additional layer beyond the 
peptidoglycan that is exceptionally rich in unusual lipids, glycolipids and 
polysaccharides (Brennan and Draper, 1994). 
 
The generation time of Mycobacterium in synthetic media or infected 
animals is approximately 24 hours (Chan and Kaufmann, 1994), so that 
primary culture may not be visible until two weeks after incubation or as 6-
8 weeks. The optimal growth temperature of (TB) is 35-37°C. All 
mycobacteria are obligate aerobes, but Mycobacterium bovis grows better 
in conditions of reduced oxygen tension. Colonies are of an off-white 
(buff) colour and except M. canetti which has smooth colonies, often have 
a dry bread crumb-like appearance. Growth is characteristically heaped up 
and luxuriant or eugonic except for bovine tubercle bacilli which produce 
small and flat dysgonic growth (Grange, 2002). 
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Mycobacterium tuberculosis complex (MTC) comprises the closely related 
species: Mycobacterium tuberculosis, M. bovis, M. africanum, M. microti 
and M. bovis BCG (Betty et al., 1998). These species are the causative 
agents of tuberculosis in humans and animals. Despite the genetically close 
relationship, the members of the Mycobacterium tuberculosis complex 
differ in their epidemiology and in their importance as a cause of 
tuberculosis. 
 
1.2.1.1 Mycobacterium tuberculosis  
M. tuberculosis is the major cause of human tuberculosis (WHO, 1996). It 
is of some degree of pathogenicity to cattle (Alhaji, 1976). Humans are the 
only reservoir for the bacterium. Many non pathogenic mycobacteria are 
components of the normal flora of humans, found most often in dry and 
oily areas (Todar, 2005) 
 
1.2. 1. 2 Mycobacterium bovis  
Mycobacterium bovis, the cause of bovine tuberculosis, and M. 
tuberculosis, the cause of classical human tuberculosis, are genetically and 
antigenically very similar and cause identical clinical disease in humans 
(Dankner et al., 1993). In humans, M. bovis is the major cause of extra-
pulmonary tuberculosis (Bonsu, Laina and Akanmori, 2001). The host 
range of M. bovis is broad, and it can cause tuberculosis in various 
domestic animals like cattle and goats and also  wild animals (Wayne and 
Kupica, 1986). Among M. bovis isolates, two subspecies have been 
described, M. bovis subsp. bovis (resistant to pyrazinamide) and M. bovis 
subsp. caprae (susceptible to pyrazinamide) (Aranaz et al., 1999). M. bovis   
subsp.  caprae was initially isolated from sheep and goats in Spain (Aranaz 
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et al., 1996); however, further studies confirmed its infectivity to humans, 
cattle, and red deer (Niemann, Richter and Ruch-Gerdes, 2002).  
 
1.2.1.3 Mycobacterium africanum 
Mycobacterium africanum consists of several strains midway between M. 
tuberculosis and M. bovis and is found in equatorial Africa. M. africanum 
is predominantly isolated in different parts of Africa (David et al., 1978). 
In certain regions, it represents up to 60% of the isolates obtained from 
patients with pulmonary tuberculosis (Haas et al., 1997).  Two major 
subgroups of M. africanum that differ in their biochemical characteristics 
have been described and these correspond to their geographical origin in 
West or East Africa (subtype 1 and subtype 11, respectively). Numerical 
analyses of biochemical characteristics revealed that subtype 1 is more 
closely related to M. bovis, whereas subtype II more closely resembles M. 
tuberculosis (David et al., 1978).  
 
1.2.1.4 Mycobacterium microti  
Mycobacterium microti, a member of the MTC was originally described as 
infective agent of a tuberculosis-like disease in voles (Microtus agrestis) in 
the 1930s (Wells, 1937). Until recently, M. microti strains were thought to 
be pathogenic only for voles and some strains were even used as live 
vaccines against M. tuberculosis. In fact, the vole bacillus proved to be 
safe and effective in preventing clinical tuberculosis in a trial involving 
roughly 10,000 adolescents in the United Kingdom in the 1950s (Hart and 
Sutherland, 1977). 
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1.2.1.5 Mycobacterium canetti  
 Mycobacterium canetti can cause tuerculosis in humans, but so far only 
few strains have been isolated and their epidemiological contribution to 
tuberculosis in humans is uncertain (Van et al., 1997).  
 
1.2.2 Mycobacterium other than tuberculosis bacilli (MOTT)  
This group has been given several collective names: atypical, anonymous, 
non-tuberculous, tuberculoid, opportunist and mycobacteria other than 
tuberculosis bacilli. Many MOTT are found in the environment, but they 
can also colonize man (e.g. in the part of previously damaged respiratory 
tract) and cause clinical infections (Watt, Rayner and Harris, 1993) (Table 
1). 
1.2.3 Other related agents including Nocardia and actinomycetes. 
The organisms are either aerobic, facultative anaerobic, or obligatory 
anaerobic. Aerobic actinomycetes belong to the order actinomycetales, 
which include more than 40 genera. Now it is well know that mycolic acid- 
containing actinomycetes form a well defined clade within the 
evolutionary radiation occupied by actinomycetes (Pascual et al., 1995). 
The redefined genus Nocardia forms a homogenous taxon which contain 
more than 60 validly well described species which can be assigned to at 
least 3 rDNA subgroups centered on the earliest described species namely 
N. asteroides, N. brasiliensis and N. otitidiscaviarum. The species that are 
considered human pathogens or have been implicated as human pathogens 
are: N. asteroide, N. nova, N. farcinica, N. brasiliensis and N. 
otitidiscaviarum (formerly N. caviae), N. trasvalesis, N. brevicatena and N. 
carnea (Goodfellow, 1998). 
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1.3 The disease 
1.3.1 Epidemiology of tuberculosis  
1.3.1.1 Transmission 
        Pulmonary tuberculosis is usually transmitted by respiratory droplets, 
discharged on coughing by a person with infectious pulmonary lesions. It 
may also result from the swallowing of organisms from hands or feeding 
utensils contaminated by the bacterium from an infected person. 
Indiscriminate spitting can contribute to transmission since sputum from 
infected persons often contains infectious bacilli (Sepkowitz et al, 1995). 
Mycobacterium bovis may penetrate the gastrointestinal mucosa or invade 
the lymphatic tissue of oropharynx. It is ingested with contaminated milk 
containing large number of organisms (Reilly and Daborn, 1995). Air- 
borne transmission of M. bovis can also occur (Dankner et al., 1993). 
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 Table I: Principal types of opportunist disease caused by  
                 mycobacteria   
                                                                                                                                 
Species Natural habitat Type of infection in man 
M. asiaticum Primates Pulmonary 
M. avium ssp. 
intracellulare 
Soil, seawater, 
animals 
Pulmonary, systemic, gastrointestinal, 
lymphadenitis 
M. cheloneii 
ssp. cheloneii 
Soil, seawater, 
animals 
Porcine heart valves, pulmonary, 
surgical wound 
M. fallax Water, soil Pulmonary, surgical wound 
M. fortuitum Water, soil, 
pulmonary 
Pulmonary, surgical wound, cutaneous, 
systemic, bone and joint 
M .haemophilum Unknown Cutaneous, subcutaneous 
M. malmoense Unknown Pulmonary 
M. marinum Aquarium, water 
fish 
Cutaneous, (swimming pool 
granuloma), joint 
M. scrofulaceum Soil, water, fomites Lymphadenitis usually (cervical, 
pulmonary disseminated) 
M. schimoidei Unknown Pulmonary 
M. simiae Primates, water Pulmonary 
M. szulagi Unknown Pulmonary, lymphadenitis, cutaneous, 
subcutaneous, bursitis 
M. ulcerans Unknown Cutaneous 
M. xenopi Soil, water Pulmonary, epididymitis 
M. kansasii Water, animals Pulmonary, systemic, skin, joints 
*Adopted from Ananthanaryanan and Piker (1990). 
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1.3.1.2 Distribution of tuberculosis in the World 
        The World Health Organization (WHO) estimated that there were nine 
million new cases of active tuberculosis and approximately 1.7 million 
deaths in 2004 worldwide (Table II). Someone in the world is newly 
infected with TB every second and one-third of the world's population is 
currently infected with TB. The AIDS epidemics are considered a major 
factor in the increase of tuberculosis cases.  HIV's suppression of the 
immune system both opens the door to new active infection and permits 
activation of latent disease. One-third of the increase in global tuberculosis 
cases over the last five years can be attributed to the HIV epidemics 
(WHO, 2006). 
 
Table II:  Estimated numbers of tuberculosis cases and rates (per 
100,000 population) by WHO in different regions, for the year 2004. 
 
Total number of cases estimated by WHO Region 
number (thousands)      rate per 100,000 
Africa 2573 356
The Americas 363 41
Eastern Mediterranean 645 122
Europe 445 50
South-East Asia 2967 182
Western Pacific 1925 111
Total 8918 140
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1.3.1.3 Tuberculosis in Sudan 
   Tuberculosis is a major public health problem in Sudan. In 2004, its 
incidence is estimated to be 220 per 100,000 people countrywide, and in 
Southern Sudan, the national tuberculosis program (NTP) reported a total 
of 2,539 cases, of which 1,064 were sputum smear-positive for TB. The 
annual risk of infection in Sudan is 1.8%, which corresponds to 82 cases of 
smear positive for TB per 100.000 populations. In a population of 
35.522.988 million in Sudan, this would correspond to just over 34 
thousand smear positive cases each year (WHO, 2006).   
  1.3.2 Pathogenesis of tuberculosis  
  After inhalation, the droplet nucleus is carried down the bronchial tree and 
implants in a respiratory bronchiole or alveolus. Whether or not an inhaled 
tubercle bacillus establishes an infection in the lung, it depends on both the 
bacterial virulence and the inherent microbicidal ability of the alveolar 
macrophage that ingests it (Edward and Kirpatrick, 1986; Dannenberg, 
1989). If the bacillus is able to survive initial defenses, it can multiply 
within the alveolar macrophage. The tubercle bacillus grows slowly, 
dividing approximately every 25 to 32 h within the macrophage. 
Mycobacterium tuberculosis has no known endotoxins or exotoxins; 
therefore, there is no immediate host response to infection. The organisms 
grow for 2 to 12 weeks, until they reach 1010 in number, which is sufficient 
to elicit a cellular immune response (Smith and Wiengeshaus, 1989) that 
can be detected by a reaction to the tuberculin skin. Before the 
development of cellular immunity, the TB spread via the lymphatics to the 
hilar lymph nodes and through the blood stream to more distant sites. 
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Certain organs and tissues are notably resistant to subsequent 
multiplication of these bacilli. The bone marrow, liver and spleen are 
almost always seeded with mycobacteria, but uncontrolled multiplication 
of the bacterium in these sites is exceptional. Organisms deposited in the 
upper lung zones, kidney, bones, and brain may find environments that 
favor their growth and numerous bacterial divisions may occur before 
specific cellular immunity develops and limits multiplication. In persons 
with intact cell-mediated immunity, collections of activated T cells and 
macrophages form granulomas that limit multiplication and spread of the 
organism.  Antibodies against M. tuberculosis are formed but do not 
appear to be protective (Reggiardo and Middlebrook, 1974). For the 
majority of individuals with normal immune function, proliferation of M. 
tuberculosis is arrested once cell-mediated immunity develops, even 
though small numbers of viable bacilli may remain within the granuloma. 
Although   a primary complex can sometimes be seen on chest radiograph, 
the majority of pulmonary tuberculosis infections are clinically and 
radiographically inapparent (Dannenberg, 1989).  
  1.3.3 Methods of diagnosis of Tuberculosis 
  1.3.3.1 Clinical diagnosis  
  1.3.3.1.1 Symptoms 
         The most important symptoms in diagnosis of pulmonary tuberculosis (PT) 
are cough (> 3 weeks), sputum production and weight loss (WHO, 1996). 
Over 90% of patients with sputum smear-positive PT develop a cough 
soon after disease onset. However, cough is not specific to PT. Cough is 
common in smokers and in patients with acute upper or lower respiratory 
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tract infection. Most acute respiratory infections resolve within 3 weeks, 
therefore, a patient with a cough for more than 3 weeks is a PT- suspected 
and must submit sputum for diagnostic microscopy (WHO, 1996).  
Patients with PT may also have other symptoms; these may be respiratory 
haemoptysis, chest pain, breathlessness, fever, night sweats, tiredness and 
loss of appetite (general or systemic). Weight loss and fever are more 
common in HIV-positive PT patients than in those who are HIV-negative. 
Conversely, cough and haemoptysis are less common in HIV-positive PT 
patients than those who are HIV-negative. This is probably because there 
is less cavitation, inflammation and bronchial irritation in HIV-positive 
patients (WHO, 1996). Pulmonary tuberculosis has to be differentiated 
from other similar disease (Table III). 
 
Table III: Differential diagnosis of pulmonary tuberculosis 
 
Differential diagnosis Pointers to correct diagnosis 
Congestive cardiac failure, 
left ventricular failure 
Symptoms of heart failure (dyspnoea, 
orthoponea, etc….) 
Asthma Intermittent symptoms, generalized 
expiratory wheezes   
Chronic obstructive 
airways disease 
Risk factor (smoking) 
Chronic symptoms, generalized wheezes 
Bronchial carcinoma Risk factor (smoking) 
 
Other infections, e.g. bacterial 
pneumonia, lung abscess 
Response to antibiotics 
Abscess with fluid 
*Adopted from WHO (1996). 
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1. 3.3.1.2 X-Rays 
       Chest X-ray is use involvement for diagnosing the disease because about 
85% of tuberculosis patients have lung PT. Usually, a person with 
pulmonary tuberculosis (PT) may show infiltrates (collections of fluid and 
cells in the tissues of the lung) or cavities (hollow spaces within the lung 
that may contain many tubercle bacilli).  However, the results of chest X-
ray cannot confirm that a person has tuberculosis disease. A variety of 
illnesses may produce abnormality on a chest X-ray which may lead a 
clinician to suspect tuberculosis. Moreover, a chest X-ray may fail to 
detect TB infection. In patients who are infected with HIV, pulmonary 
tuberculosis disease may have an unusual appearance on chest X-rays. And 
some chest X-rays may even appear entirely normal (Grzybowski et al., 
1971). 
   
1.3.3.1.3 Tuberculin test 
          Tuberculin is a purified protein derivative (PPD) from tubercle bacilli. 
Thus, another name for tuberculin is PPD. Following infection with M. 
tuberculosis, a person who is intradermally injected with PPD develops 
hypersensitivity to tuberculin (WHO, 1996). When tuberculin is injected in 
the skin of an infected person, it produces a delayed local reaction 
(hypersensitivity) after 24-48 hours with signs of induration and erythema. 
Measuring the diameter of skin induration (thickening) will tell whether 
the test is positive or negative.  A positive result may be due to active 
infection, old infection, cross-reaction with other mycobacteria or 
vaccination with BCG (WHO, 1996). 
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Value of a negative tuberculin skin test  
        The tuberculin test is negative when the diameter of skin induration is less 
than 10 mm. This is regardless whether or not the person has had BCG. A 
negative test does not ascertain that some one does not have tuberculosis as  
a recent infection may exist.  
  
Conditions which may suppress the tuberculin skin test  
        The reaction would be suppressed due to one or more of the following 
conditions: HIV infection, malnutrition, severe bacterial infections 
including infection with TB itself, viral infections, e. g measles, chicken 
pox and glandular fever, cancer and immunosuppressive drugs intake, e. g 
steroids. 
 
Value of a positive tuberculin skin test  
   The criterion for a positive tuberculin test depends on whether a child had 
previous BCG vaccination or not. This is because a reaction to tuberculin 
is usual after a previous BCG vaccination, at least for several years. This 
reaction is usually a weaker reaction (diameter often less than 10 mm) than 
the reaction to natural infection with M. tuberculosis. Therefore, in a child 
who has no BCG vaccination, a tuberculin test is positive when the 
diameter of skin induration is 10 mm or more. In a child who had BCG 
vaccination, a test is positive when the diameter of induration is 15mm or 
more. A positive tuberculin test is only one piece of evidence in favor of 
diagnosis of tuberculosis. The older the person and greater the diameter of 
induration (above 10-15 mm), the stronger is that one piece of evidence 
(WHO, 1996).  
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1.3.3.2   Laboratory diagnosis  
1.3.3.2.1 Microscopic Examination 
    The “acid-fast” staining reaction of mycobacteria, along with their beaded 
and slightly curved shapes, is a valuable aid in the early detection of 
infection and in the monitoring of therapy (Barrow and Feltham, 1994). 
The finding of acid-fast bacilli in the sputum, combined with a history of 
cough and weight loss and a chest X-ray showing a pulmonary infiltrate, is 
often considered presumptive evidence of active tuberculosis and sufficient 
to initiate therapy. Two procedures are commonly used for acid–fast 
staining: the carbolfuchsin methods, which include the Ziehl-Neelsen and 
Kinyon methods, and a fluorochrome procedure using auramine-O or 
auramine-rhodamine dyes. Several quantitative studies have shown that 
there must be 5,000 to 10,000 bacilli per milliliter of specimen to allow the 
detection of bacteria in stained smears (Hoby et al., 1973). In contrast, 
only 10 to 100 organisms are needed for a positive culture (Yeagaer et al., 
1967). The sensitivity of sputum smear microscopy has been reported to be 
between 22-80% of culture-confirmed tuberculosis (Colebunders and 
Bastian, 2000). Acid-fast bacilli are approximately 0.2 – 0.8 x 1 – 10 µm 
and appear as slender, straight, curved or bent. With carbolfuchsin 
staining, TB look as fine red rods, slightly curved, more or less granular, 
isolated, in pairs or in groups, standing out clearly against the blue 
background. With fluorochrome staining, tubercle bacilli emit a bright 
yellow fluorescence against a pale yellow (potassium permanganate) or 
orange (acridine orange) background. Some mycobacteria other than M. 
tuberculosis may appear pleomorphic, ranging in appearance from long 
rods to coccoid forms, with uniform distribution of staining properties. 
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Organisms other than mycobacteria may demonstrate various degrees of 
acid-fastness. Such organisms include Rhodococcus spp., Nocardia spp., 
Legionella spp., and the cysts of Cryptosporidium and Isospora spp.. 
Rapidly growing mycobacteria may vary in their abilities to retain acid-fast 
stains (WHO, 1998).    
 
    1.3.3.2.2 Decontamination and homogenization of sputa 
            The majority of specimens submitted for mycoacterial culture consist of 
organic debris, such as mucin, tissue, serum, and other proteinaceous 
material that is contaminated with organisms. A typical example of such 
specimens is sputum. Laboratories must process these specimens so that 
contaminating bacteria that can rapidly outgrow mycobacteria are either 
killed or reduced in numbers, and mycobacteria are released from mucin 
and/or cells. After decontamination, mycobacteria are concentrated usually 
by acid-fast stain and culture. Unfortunately, there is no one ideal method 
for decontamination and digestion of clinical specimens. The commonly 
used digestion-decontamination methods are the sodium hydroxide 
(NaOH) method, the zephiran-trisodium phosphate method and the N-
acetyl-L-cysteine (NALC) method (Kent and Kuipca, 1985).  
 
1. 3. 3. 2. 3 Culture methods  
        Culture is much more sensitive than microscopy, being able to detect as 
few as 10 bacteria/ml of material (Yeagaer et al., 1967). In general, the 
sensitivity of culture is 80–85% with a specificity of approximately 98% 
(Morgan et al., 1983). Three different types of traditional culture media are 
available: egg-based (Lowِenstein–Jensen), agar-based (Middlebrook 7H10 
or 7H11 medium) and liquid (Middlebrook 7H12). In the agar medium, 
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growth of mycobacteria tends to be slightly better and more rapid than on 
the egg-based medium. Growth in liquid media is faster than growth on 
solid media, Growth may be observed in 10 to 12 days in contrast to 18 to 
24 days on solid media (Patrick, 2000). A major improvement in 
mycobacteriology has been the development of commercial broth systems 
for mycobacterial growth detection. 
Isolation of mycobacteria  
             Mycobacteria are often scant in pathological materials and not uniformly 
distributed. Many other organisms may be present and the culturing 
methods used in other bacteriological examinations are useless. Isolation 
methods depend on homogenization of the suspected specimens with a 
reagent that reduces the viscosity of the preparation and to free the bacilli 
from the mucous, cells or tissue in which they may be embedded 
(Collins,Yates and Uttley, 1989). 
 
BACTEC APB SYSTEM  
        BACTEC APB System developed by Middlebrook and others in 1977. 
The BACTEC is an automated early detection system in which specimens 
are cultured in a liquid medium containing C14-labelled palmitic acid. 
Growing of mycobacteria will utilize the acid, releasing radioactive carbon 
dioxide which is measured in the bactec instrument. Detection time for 
positive culture is decreased to less than 7 days for non tuberculosis 
mycobacteria and to an average of 9 to 14 days for M. tuberculosis 
(Morgan et al., 1983). 
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       Mycobacteria growth indicator tube  
       The mycobacteria growth indicator tube (MGIT) (Nippon Becton 
Dickinson Co., Ltd., Tokyo), which is a recently introduced 
nonradiometric culture system, uses an oxygen-quenched fluorescent 
indicator. A fluorescent compound, ruthenium metal complex, is 
embedded in silicone on the bottom of 16X100 mm round-bottom tubes. 
Actively respiring mycobacteria consume the dissolved oxygen and allow 
the fluorescence to be observed with a 365 nm UV transilluminator. The 
mean time for detection of the Mycobacterium tuberculosis complex is 16 
days (Abe et al., 1992).  
 
        Septi–Chek  
     This is a biphasic medium system (Roche) consisting of an enriched 
selective broth and a slide with nonselective Middlebrook agar on one side 
and with two sections on other side, one with NAP and egg-containing 
agar, the second with chocolate agar for detection of contamination. This 
system has also been found to be quite useful for rapid detection of growth 
of mycobacteria (Isenberg et al., 1991).  
 
     MB-REDOX 
MB-REDOX (Biotest AG, Frankfurt, Germany) is the serum- 
supplemented, modified Kirchner medium (4ml), containing a colorless 
tetrazolium salt, special vitamin complex and the antibiotic mixture, PACT 
(polymixin B, amphotericin B, carbenicillin and trimethoprim). In this 
method, the tetrazolium salt is reduced by the redox system of the 
mycobacteria to a brownish formazan. This formazan is water insoluble 
and is easily detected by the naked eye. The mean time for confirmation of 
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M. tuberculosis complex is 15 days for processing of the specimens with 
the MB-REDOX (Cambau et al., 1999) 
 
1.3.3.2.4 Immunodiagnostic tests 
  The first immunodiagnostic test was the tuberculin skin test. The 
shortcomings of this test include its inability to distinguish active disease      
from past sensitization and unknown predictive accuracy (Snider, 1982). 
Until 2001, the only test used to diagnose latent tuberculosis infection 
(LTBI) was the tuberculin skin test. However, in 2001 a new test 
(QuantiFERON®-TB) was developed. Quantification of gamma interferon 
forms the basis of the test (Streeton et al., 1998). 
 
MPB64-ICA is a rapid immunochromatographic identification test for M. 
tuberculosis complex that uses anti-MPB64 monoclonal antibodies. 
Monoclonal antibodies are produced from hybridomas obtained by the 
fusion of P3UI myeloma cells with spleen cells of mice immunized with an 
MPB64 antigen. This is another approach for detection of mycobacterial 
antigen in liquid cultures after several days of incubation (Tomiyama, 
Matsuo and Abe, 1997). 
 
1.3.3.2.5    Biochemical tests 
Selected biochemical tests that are commonly used in distinguishing 
between species of the genus Mycobacterium are shown in Table (IV). 
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1.3.3.2.6 Molecular diagnosis of tuberculosis 
Gene probes 
       The first step in the application of molecular biology techniques was the 
introduction of the specific labelled gene probes that could detect 
mycobacteria by DNA hybridization. The detection limit for such probes is 
however of the order of 100000 bacteria per gram, whereas the number of 
bacilli in many clinical samples is much lower than this. Gene probes as 
such are therefore not sufficiently sensitive for the direct detection of 
mycobacteria in clinical specimens (Bull and Shanson, 1992).  
 
Table IV. Biochemical characteristics for distinguishing between  
                    species of the genus Mycobacterium     
Organism Niacin 
test 
Nitrate 
reduction 
Catalase 
(68 ºC) 
Tween 
hydrolysis 
(10 days) 
Arylsulfatase 
(3 days) 
Urease 
M. tuberculosis + 3-5+ - -/+ - + 
M. africanum V V - - -  
M. bovis V - - - - + 
M. ulcerans - - + - -  
M. kansaii - 1-5+ + + - + 
M. marinum V - -/+ + -/+  
M. simiae + -/+ + - - - 
M. gordonae - - + + - - 
M. xenopi - - + - +/- - 
M. intracellulare 
avium complex 
- - + - - - 
M. fortuitum - 2-5+ + +/- + + 
M. smegmatiz - 1-5+ +/- + -  
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* Adopted from Sommers (1987).   
Key: += 84 % of strains positive; +/-= 50 to 84 % positive; -/+= 75 - 89 % 
negative; - = 89 % of strains positive; v= variable; blank space= little or no 
data.  
 
       Polymerase chain reaction (PCR)   
The polymerase chain reaction (PCR) is a rapid and powerful procedure 
for the in vitro generation of millions of copies of specific 
deoxyribonucleic acid (DNA) segment. In the research laboratory, this 
procedure can produce a positive result from specimens containing as few 
as 10 bacilli (Shinnick and Good, 1995). In clinical respiratory specimens 
that are acid fast bacilli-positive smear, the sensitivity of the amplification 
methods is approximately 95%, with a specificity of 98%. In specimens 
that gave fewer organisms and gave AFB-negative smears, the nucleic acid 
amplification test is positive in 48–53% of patients with culture-positive 
tuberculosis and the specificity remains approximately 95% (American 
Thoracic Society, 1997). 
 
Single strand conformation polymorphism (SSCP) 
In combination with PCR, SSCP has been applied for the detection of 
resistance to rifampicin, isoniazid and streptomycin (Telenti et al., 1993).  
 
Sequencing  
The target use of this method is the 16S ribosomal ribonucleic acid 
(rRNA); the attractive feature of this molecule is that it contains conserved 
agent-specific as well as various specific regions. Therefore, it was straight 
forward to use this molecule or the gene coding for the 16S rRNA, namely 
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the 16S ribosomal deoxyribonucleic acid (rDNA), as a powerful target for 
amplification of mycobacteria, both at the genus and species level (Jonas, 
et al, 1993).  
 
Restriction fragment length polymorphism (RFLP) 
RFLP analysis of specific fragment of DNA of species of MTC with use of 
the restriction enzyme MboII was performed to detect the mutation at 
codon K43R (Naire et al., 1993). MboII is an enzyme (restriction 
endonuclease) that recognizes specific palindromic target nucleotide 
sequences and cleaves double-stranded DNA near recognition site.  
Real time-PCR  
Real-time PCR has revolutionized the way clinical microbiology 
laboratories diagnose many human microbial infections. In general, both 
PCR and amplified product detection are completed in an hour or less, 
which is considerably faster than conventional PCR detection methods. It 
is also called Quantitative-PCR that simultan easily amplify and quantify a 
target DNA molecule. Real-time PCR assays provide sensitivity and 
specificity equivalent to that of conventional PCR combined with southern 
blot analysis, and since amplification and detection steps are performed in 
the same closed vessel, the risk of releasing amplified nucleic acids into 
the environment is negligible (American Society for Microbiology, 2006). 
The technique was successfully used to diagnosis M. tuberculosis 
(American Society for Microbiology, 2006). 
 
1.3.4 Chemotherapy of tuberculosis 
1.3.4.1   History of chemotherapy 
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Prior to the introduction of streptomycin in 1940, there was no effective 
treatment for tuberculosis. The development of p-aminosalicylic acid and 
isoniazid in 1952 has enhaced the probability of achieving curative 
therapy. The introduction of rifampicin in 1971 further improved 
effectiveness of   chemotherapeutic regimens. In 1980 the success of 6 
months regimens allowed clinicians to shorten the duration of treatment in 
some patients (Harding and Bailey; 1994). However, there are still 
problems in treating tuerculosis including poor patient compliance, 
multiple drug resistance and altered host immune impairment, typically 
include one or more of the following: malnourishment, acquired immune 
deficiency syndrome (AIDS), hematologic or reticuloendothelial 
malignancy and chronic renal failure (Harding and Bailey,  1994). 
   
1.3.4.2 Drugs used for treatment of tuberculosis 
Antituberculous drugs can be divided into first-line drugs, second-line 
drugs and experimental drugs. First line drugs include isoniazid, 
rifampicin, pyrazinamide, ethambutol, and streptomycin. Second-line 
drugs include p-aminosalicylic acid, ethionamide, cyclosyrine, kanamycin, 
capreomycin, and amikacin. Short notes on first-line drugs are outlined 
below.  
1.3.4.2.1 Rifampicin 
Rifampicin (RIF), a semi-synthetic derivative of the natural product 
rifampici, obtained from culture filtrates of Streptomyces mediterranei, 
was introduced in 1972 as a tubercular drug (Woodley et al, 1972). 
Rifampicin is extremely effective against M. tuberculosis (MIC is 1.0-0.2 
ug/ml) and its rapid bactericidial activity (Mitchison, 1985) helped to 
shorten the course of treatment against drug-susceptible infections. The 
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target of rifampicin action in M. tuberculosis has been assumed to be 
mycobacterial RNA polymerase (Siddiqi, 1981), but later it was known to 
arise as a result of missense and other mutations occurring in a discrete 
region of the rpoB gene (Jin and Gross, 1988). 
Resistance to rifampicin is increasing rapidly as a result of its widespread 
use. Rifampicin-resistant tuberculosis, often observed in conjunction with 
isoniazid resistance, leads to a longer treatment-period and significantly 
poorer chemo-therapeutic outcomes. Resistance has been observed in 3.9% 
of different types of cases, but in 9.0% of patients who have been 
previously treated for tuberculosis (Tsukamura, 1972).  
The vast majority (93%) of rifampicin resistance-conferring mutations in 
the mycobacterial rpoB encoded RNA polymerase are single nucleotide 
changes that result in single amino acid substitutions (Honore and Cole 
, 1993). The remaining mutations are insertions (3%) and deletions (4%),  
Other species of the genus Mycobacterium are found to have the same 
mutations in the same gene but in different locations (Honore et al, 1993; 
Williams et al., 1994). 
 
1.3.4.2.2 Isoniazid 
Isoniazid (INH) was discovered in 1945 to be an effective antituberculous 
drug after nicotinamide was found to be a tuberculostatic agent (Chorine, 
1945). Bactericidal effects of INH are exerted only against actively 
growing organisms. Although the mechanism of action remains unknown, 
it is suggested that INH exerts its effects on lipids, especially mycolic acid 
components of the cell wall, nucleic acid biosythesis, and glycolysis 
(Harding and Bailey, 1994). Using INH as a single agent allows the 
development of mutants resistant to it when the number of organisms 
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exceeded 1X106. Thus, active tuberculosis must be treated with at least two 
drugs (Harding and Bailey, 1994). INH is available as an oral tablet, 
pediatric syrup, and in injectable form. The usual dose is 3 to 5 mg/kg 
body weight per day, or 300 mg/d in adults, which produces a peak 
concentration of 5 mg/kg. 
 
1.3.4.2.3 Pyrazinamide  
  It is asynthetic pyrazine analog of nicotinamide and bactericidal only 
against intracellular bacteria at an acidic pH. It is uniquely effective in 
eliminating potential persisters and is used during the first 2 months of 
chemotherapy to reduce total length of therapy. Resistance develops 
rapidly if it is used alone (McDermott and Tompsett, 1954). The daily 
dosage is 20 to 35 mg/kg body weight given orally in three or four doses 
not to exceed 3 g/d. 
 
1.3.4.2.4 Streptomycin  
It was the first clinically effective antibiotic available for treatment of 
tuberculosis. Streptomycin is bactericidal in an alkaline environment and is 
effective only against actively growing extracellular organisms. It is only 
available as injectable form; peak serum concentration of approximately 40 
mg/ml is reached about one hour after intramuscular injection using a dose 
of 15 mg/kg (standard dose 10-15 mg/kg). Most strains of M. tuberculosis 
are inhibited in vitro at 8 mg/kg. Resistance to streptomycin among new 
cases is found in 2% of isolates, though because of mutation, resistance 
develops in as many as 80% of patients after 4 months of single drug 
therapy (Harding and Bailey, 1994).  
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1.3.4.2.5 Ethambutol  
Despite being bacteriostatic, it was found to be an effective agent in the 
treatment of (PT). Prior to the use of RIF, ethambutol was commonly used 
with INH and is effective when used for 18 months. Its major use with 
INH is to allow INH to perform its bactericidal activity and eliminate 
persisters without developing drug resistant genetic mutants. Following the 
standard dose of 15 mg/kg, peak plasma concentration is about 4mg/ml, 
occurring in two to four hours after injection (Harding and Bailey, 1994).  
 
1.3.4.3 Current chemotherapy of tuberculosis 
The World Global Tuberculosis program emphasizes the importance of 
standardized treatment administered under direct observation as one of the 
important components of its global strategy to control tuerculosis. The 
''directely observed treatment short course” (DOTS) strategy is today 
recognized as the only means by which effective tuberculosis control could 
be achieved.  
 
The earlier two years regimen of streptomycin, isoniazid and p-amino 
salicylic acid has been replaced by much more acceptable orally 
administered regimens based on initial intensive 2-month phase and a 4-6-
month continuation phase depending on the WHO treatment category. 
Significant modifications in the WHO guidelines of 2003 (WHO, 2003) 
from the previous guidelines of 1997 (WHO, 1997), as shown in Table V 
are (i) tuberculosis patients with concomitant HIV infection are included in 
category I; and (II) the treatment for category III patients is the same as 
that for category 1 patients, i.e., a 4-drug initial phase followed by a two-
drug continuation phase.  
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Table V:  Treatment categories and recommended short course drug   
                 Regimens 
        
Treatment 
Category  
Patient definition  Initial 
phase(a) 
Continuation 
phase 
I New, smear –positive  
New, smear-negative 
with extensive lung 
involvement  
Severe non-pulmonary 
disease 
HRZE  
or 
HRZS 
4 months’ HR  
or  
4 months’ H3 E3  
or  
6 months’ HE  
II Sputum smear–positive 
after relapse 
Treatment failure or 
interruption of treatment 
HRZE  
or 
HRZES 
 5 months’ HRE  
 
5 months’ 
H3R3E3 
III New, smear negative 
(other than category 1) 
and less severe non–
pulmonary disease 
HRZ  4 months’ HR or 
4 months’ H3E3 
or  
6 months’ HE 
IV Chronic disease(b) Adviced to use second line drug. 
 
 
Key: H, isoniazid; R;  rifampicin; Z; pyrazinamide; E, ethambutol; S, 
streptomycin; (a) daily or thrice weekly for 2 months; (b) Smear-positive 
after supervised re-treatment; the subscript numeral '3' indicates thrice-
weekly. 
* Adopted from WHO (2003) 
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1.3. 4.4  Multi-drug resistance tuberculosis(MDR-TB)  
 
     MDR-TB strains are generally considered to be those resistant to at least 
INH and RIF (Goble et al., 1993). These strains have been described 
worldwide, and their existence poses a serious threat to TB control 
programs in many countries (Frieden et al., 1995). The frequency of 
secondary resistance is more common than primary one. In principle, 
treatment of patients with MDR-TB is substantially more difficult than 
individuals infected with drug-sensitive strains. MDR-TB strains could 
arise as a consequence of sequential accumulation of mutations conferring 
resistance to a single therapeutic agent, or only sinlge-step process such as 
acquisition of MDR element, or mutation that alters, for example, cell wall 
structure. All available evidence indicates that the former process is critical 
to the emergence of these organisms (Ramaswamy and Musser, 1998). 
1.3.4.5 The mechanism of drug resistance 
     Mycobacterium tuberculosis and other members of the M. tuberculosis 
complex use several strategies to resist the action of antimicrobial agents. 
First, the mycobacterial cell is surrounded by a specialized, highly 
hydrophobic cell wall that results in decreased permeability to many 
compounds (Jarlier and Nikaido, 1994). Active drug efflux systems and 
degrading or inactivating enzymes and the genes that are associated with 
these functions, have been found in M. tuberculosis (Cole et al., 1998). 
However, genetic studies have shown that resistance of M. tuberculosis to 
antimycobacterial drugs is the consequence of spontaneous mutations in 
genes that encode either the target of the drug, or enzymes that are 
involved in drug activation. Resistance-associated point mutations, 
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deletions, or insertions have been described for all first-line drugs 
(isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin) and for 
several second-line and newer drugs (ethionamide, fluoroquinolones, 
macrolides and nitroimidazopyrans) (Stover et al., 2000). However, no 
single genetic alteration has yet been found that results in the MDR 
phenotype (defined as resistance at least to isoniazid and rifampicin). 
Rather, MDR develops by sequential acquisition of mutations at different 
loci, usually because of inappropriate patient treatment. Because MDR 
strains are the result of cumulative mutations, growth of M. tuberculosis 
can successfully be controlled in the host by concomitant treatment with 
more than one drug. Thus, treatment regimens that consist of three to four 
drugs are used routinely to treat patients with tuberculosis. 
 
The World Health Organization,  Global Tuberculosis Programme and 
International Union against Tuberculosis and Lung Disease (WHO, 2000) 
has recently recommended the following terminology changes for the 
different types of resistance to antituberculosis drugs. Isolation of drug-
resistant M. tuberculosis from patients without a history of previous 
treatment should be referred to as 'drug resistance among new cases' 
(instead of 'primary resistance'). Isolation of a drug-resistant strain from 
patients who have been treated for tuberculosis for at least 1 month should 
be referred to as 'drug resistance among previously treated patients' 
(instead of 'acquired resistance'). The latter occurrence is more common, in 
which inadequate treatment or lack of adherence by the patient results in 
the selection of naturally occurring resistant mutants. Less common is 
cross-resistance, in which resistance occurs between drugs that are 
chemically related and/or have a similar target within the mycobacterial 
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cell (rifampin and other rifamycin derivatives, or isoniazid and 
ethionamide) (DeBarber et al., 2000). 
 
One of the main reasons for treatment failure and fatal clinical outcome in 
tuberculosis patients is resistance to rifampicin (Mitchison and Nunn, 
1986). In addition to a significant early bactericidal effect on metabolically 
active M. tuberculosis, rifampin also exhibits excellent late sterilizing 
action on semidormant organisms undergoing short bursts of metabolic 
activity. The recognition of this late effect of rifampicin, and the additional 
effectiveness of pyrazinamide, has allowed for the reduction of routine 
tuberculosis treatment from 1 year to 6 months (Grosset, 1978). 
Monoresistance to isoniazid is quite common, but monoresistance to 
rifampicin is rare. Instead, rifampicin resistance occurs most often in 
strains that are also resistant to isoniazid; thus, rifampicin resistance can be 
used as a surrogate marker for MDR. 
 
1.3.4.6 Drug susceptibility and resistance determination     
            methods 
 
Direct Method  
Drug susceptibility testing can be performed based on mycobacterial 
cultivation on solid media, either egg or agar-based. In the direct test, a set 
of drug-containing and drug-free media are inoculated directly with 
concentrated specimens. The advantage of the direct method over the 
indirect one is that the results are available sooner (within 3 weeks on agar 
plates) and represent the patient’s original bacterial population. 
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Indirect Method 
In the Indirect test, the pure culture is inoculated in drug-containing and 
drug-free slopes either in egg-based Lowenstein-Jensen medium or agar 
based 7H11 medium. 
 
1.3.4.6.1 Phenotypic methods  
Absolute concentration method 
This method uses a standardized inoculums grown on drug-free media and 
media containing graded concentrations of the drug (s) to be tested                          
and resistance is expressed in terms of the lowest concentration of the drug 
that inhibits growth; i.e. minimal inhibitory concentration (MIC). This 
method is greatly affected by the viability of organisms (Inderlied, 1991). 
 
Resistance ratio method  
This would compare the growth of unknown strains of tubercle bacilli with 
that of standard laboratory strain (H37Rv). Paralled sets of media 
containing two-fold dilutions of the drug are inoculated with standard 
strains of tubercle bacilli. Resistance is expressed as the ratio of the MIC 
of the test strain to the MIC of the standard strain in the same set. This test 
is also greatly affected by the inoculum size as well as the viability of the 
strains. In addition, any variation in the susceptibility of the standard strain 
also affects the resistance ratio of the test strain (Inderlied, 1991). 
 
Proportion method 
This method enables a precise estimation of the proportion of mutants 
resistant to a given drug. Several 10-fold dilutions of inoculum are planted 
onto both control (drug-free) and drug-containing media; at least one 
dilution should yield isolated countable (50-100) colonies. When these 
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numbers are adjusted by multiplying by the dilution of the inoculum used,                          
the total number of viable colonies on the control medium, and the number 
of mutant colonies resistant to the drug concentrations tested may be 
estimated. The proportion of bacilli resistant to a given drug is then 
determined by expressing the resistant portion as a percentage of the total 
population used (Canetti et al., 1969). The proportion method is currently 
the method of choice for estimating drug resistance and its principle is 
being applied to the following rapid testing methods: BACTEC 460, 
MGTT 960, MB /Bac T system and ESP 11 system.   
 
Recently developed phenotypic methods  
E-test (commercially available as AB BIODISK) 
The E-test is based on determination of drug susceptibility using strips 
containing gradients of impregnated antibiotics. There are reports about a 
high rate of false resistance by this method when compared with BACTEC 
or conventional LJ proportion methods (Hausdorfer et al., 1998).  
 
Microwell Alamar blue assay and microplate  
tetrazolium reduction assay  
        
These tests are colorimetric based on the oxidation-reduction of the      dye 
Alamar blue or MTT 3- (4, 5 dimethylthiazol-2-yl) -2, 5-diphenyl 
tetrazolium bromide). Drug resistance is detected by the reduction of the 
dye from blue to pink due to the oxidation-reduction metabolism of viable 
organisms (Franzblau et al., 1998 and Mshana et al., 1998). 
 
Mycolic acid index susceptibility testing 
This is a modification of the original mycolic acid analysis by HPLC 
where a coumarin compound is used as a fluorescent derivatizing agent of 
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mycolic acid instead of p-bromophenacyl bromide. The drug sensitivity is 
assessed by measuring the total area under mycolic acid (TAMA), 
chromatographic peaks of a culture of M. tuberculosis, and this area has a 
very good correlation with log CFU per milliliter. Depending on the singal 
and quantification of this procedure, drug susceptibility pattern can be 
carried out as a rapid method (Vlader-Salvado et al., 2001).  
 
Microscopic observation of broth cultures–drug 
susceptibility assay  
This novel method of microscopic observation of broth culture with drugs 
is used for drug sensitivity testing. It is a relatively inexpensive and fairly 
rapid drug susceptibility testing method with a high sensitivity and 
specificity and is suited for disease endemic developing countries (Cavieds 
et al., 2000).  
  
Micro-colony detection  
This employs observation of micro-colonies of M. tuberculosis with the 
help of a microscope, on a thin layer of 7H11 agar plate and is used for 
drug sensitivity testing. It is less expensive than the conventional 
proportion method, and may be a good low-cost alternative for resource- 
poor countries (Meija et al., 1999).  
 
Luciferase report phage assay 
In this technique, viable mycobacteria are infected with reporter phages 
expressing firefly luciferase gene. Easily detectable signals are seen a few 
minutes after the infection of M. tuberculosis with reporter phages. Light 
production requires metabolically active M. tuberculosis cells in which 
reporter phages replicate and luciferase gene is expressed. When drug-
 35
susceptible M. tuberculosis strains are incubated with specific anti-
tuberculosis drugs, they fail to produce light after infection with luciferase 
reporter phages. In contrast, drug resistant strains are unaffected by the 
drugs and produce light at levels equivalent to those documented for 
untreated controls after infection with reporter phages (Riska et al., 1999). 
The other reporter molecule described is the green fluorescence protein 
(GFP) of the jellyfish Aequorea victoria. This reporter system does not 
require co-factors or substances due to intrinsic fluorescence nature of the 
GFP. These tests have generally good sensitivity and reproducibility but 
are yet to be used in routine clinical laboratories. 
 
1.3.4.6.2 Genotypic methods  
 
These are essentially required for the rapid identification of MDR TB 
strains.  In contrast to other bacteria, drug resistance in M. tuberculosis is 
not plasmid mediated. Most of the molecular events relating to the 
chromosomal basis of drug resistance have been elucidated. Refers to 
simultaneous resistance to at least RIF and INH (with or without resistance 
to other drugs). Genetic and molecular analysis of drug resistance in MDR 
TB suggests that the bacilli usually acquire resistance either by titration of 
the drug through overproduction of the target or by mutation. MDR TB 
usually results from accumulation of individual target genes (Rattan, Kalia, 
and Ahmad, 1998). 
 
Automated DNA sequencing  
Among the molecular techniques available to detect M. tuberculosis drug 
resistance, DNA sequencing of PCR amplified products are most widely 
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used and is becoming the gold standard for this purpose. The DNA 
sequencing is used for characterization of the mutation responsible for 
drug resistance. This technique is being mainly used for drugs like 
rifampicin, isoniazid and streptomycin (Kapur et al., 1995). 
 
PCR Single strand conformation polymorphism (PCR SSCP) 
The combination of PCR and SSCP has been applied for the detection of 
resistance to rifampicin, isoniazid and streptomycin (Telenti et al., 1993).  
 
Polymerase chain reaction based on universal heteroduplex generator 
assay (PCR HDG ) 
  This assay is performed by mixing amplified DNA from the test organisms 
and susceptible control strains to obtain hybrid complementary DNA. If a 
resistant strain is present, the mutation will produce a heteroduplex which 
has different electrophoretic mobility compared with the homoduplex 
hybrid (no mutation present). The PCR-HDG is used to detect all 
Rifampicin-resistant strains having mutation within the 305-bp region of 
the rpo B gene (Williams et al., 1998). This assay can be used cost-
effectively only in reference laboratories with a large number of specimens 
where the cost of the test per specimen can be reduced. 
 
Line probe assay (solid phase hybridization assay) 
The line probe assay or LIPA is a commercial test for the rapid detection 
of M. tuberculosis complex and Rifampicin resistance. The LIPA is based 
on the hybridization of amplified DNA from the cultured strains or clinical 
specimens to probes encompassing the core region of rpo B gene of M. 
tuberculosis, which is immobilized on a nitrocellulose strip. The absence 
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of hybridization of amplified DNA to any of the sensitive sequence 
specific probes indicates mutations that may encode resistance; likewise, if 
hybridization to the mutation specific probes occurs, the mutation is 
present (Beenhouwer et al., 1995). 
 
Miscellaneous genotypic methods  
 
These include new genotypic techniques for the rapid detection of drug 
resistance in M. tuberculosis: cleavage fragment length polymorphism 
(CFLP) (Sreevatsan et al., 1998), dideoxy fingerprinting (ddf) (Filmlee et 
al., 1995), hybridization protection assays (Miyamoto et al., 1996), a 
technique based on reverse transcriptase strand displacement, amplification 
of m-RNA 18, RNA-RNA duplex base pair mismatch assay (Nash, 
Gaytan, and Iderlind, 1997 ) and DNA sequence analysis using fluorogenic 
reporter molecules (Piatek et al .,1998). However, these techniques have 
not been extensively studied and have not been further validated with 
clinical isolates.  
 
Restriction fragment length polymorphism typing (RFLP) 
The principle behind the RFLP technique is that if a single base    
difference between otherwise two identical pieces of double stranded DNA 
is lying within the recognition site of restriction endonuclease, then 
digestion of both samples with restriction endonuclease will produce 
different products which can be resolved by electrophoresis resulting in 
different handling patterns called genomic or DNA fingerprints. Difference 
in banding patterns are referred to as RFLPs. RFLP typing of M. 
tuberculosis isolates are useful for epidemiological investigations in the 
spread of particular strains especially multi-drug resistant strains and also 
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to learn about replacement following successful treatment, and to know 
whether it is due to endogenous reactivation or exogenous reinfection (Das 
et al., 1995)  
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Patients    
         This study was targeting the pulmonary tuberculosis-suspected patients, 
who their sputa were found positive for acid fast bacilli by the tuberculosis 
laboratories in the health institutions they visited. Three hundred and 
twenty nine patients, who attended Abu-Anga Teaching Hospital, El-Shaab 
Teaching Hospital and the National Health Laboratory, Khartoum, during 
the period from October 2005 to December 2006, with symptoms of 
pulmonary tuberulosis, were the cases of this study. Age of the patients 
varied between 5 and 70 years. Data about all patients were taken 
according to the questionaire form informed conscent (Appendix), which 
contains patient’s number, name, age, gender, tribe, occupation, residence, 
whether new case, relapse, interruption or failure of treatment.  
 
       2.2 Method of sample collection 
        Sputum samples were collected according to WHO criteria (1996) in 
sterile, plastic, wide-mounted and leak-proof containers, wrapped with 
sufficient absorbent material to soak up all the specimen should the 
container break and within a robust outer plastic box of cardboard. Sputum 
samples were not saliva but coughed up from the lungs after three times 
mouth wash. Samples were processed in the same day of receival. 
 
2.3 Equipment, plastic and glassware 
        Incubator (Fisher Scientific,  U.  S. A), Olympus microscope (Olympus 
Co., Tokio), safety cabinet class II for culture (Heraeus, Germany), glass 
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microslide with cut edges (Jisico,China,), safety cabinet for PCR mixture 
(Biometra, Germany), pH meter, thermal cycler (Biometra, Germany), 
plastic sputum containers (40 ml), vortex mixer, universal bottles, 
disposable sterile eppendorf tubes, plastic disposable pipettes, plastic 
disposable conical tubes (50 ml) (Cornindny Ecorparated, Canada), 
inspissator (Jisico, China), OvenBs (Gallenhamh, England), referigerator 
(Lec, Tokio), centrifuge (B&T, England) UV Transilluminator (Biometra, 
Germany).  
 
        2.4 Asepsis and sterilization:  
       2.4.1 Flaming: 
       Flaming was used to sterilize slides, cover slips and glass rods. 
        
2. 4. 2 Red heat: 
       Red heat was used to sterilize wire loops by holding them over Bunsen 
burner flame until became red. 
 
2.4.3 Hot air oven: 
        Hot air oven was used to sterilize metals, glassware such as test tubes, 
graduate pipettes, flasks, The holding period was one hour and temperature 
was 160°C. 
 
2.4.4 Moist heat (autoclaving): 
       Media, solutions and plastic ware were sterilized by autoclaving at 121°C 
(15 Ib/inch2) for 15 minutes. 
 
       2.4.5 Irradiation: 
        Ultraviolet irradiation for 20 minutes was used to sterilize media pouring 
room. 
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       2.4.6 Disinfection: 
       Phenol disinfectant and 70% alcohol were used for disinfecting the floor 
and working bench in the laboratory. 
 
       2.5   Staining (Ziehl-Neelsen’s stain)  
       Formula for basic stain solution 
       Solution A: Saturated alcoholic solution of fuchsin 
       Basic fuchsin  3g 
       Ethanol, 96 %                                                    100ml  
       Solution B: Phenol solution, 50 g/l (5%), aqueous  
       Phenol crystals  10g 
       Distilled water  200ml 
       Then:  
       Solution A 10ml 
       Solution B 90ml 
      Formula for decolorizing agent  
       Ethanol, 96% 970ml 
       Hydrochloric acid 30ml  
       Formula for counterstaining solution 
       Methylene blue  0.3g 
       Distilled water  100ml 
        
Procedure: Thin smears from primary and pure colonies were prepared, 
air-dried and fixed by gentle heat. Smears were flooded with carbol 
fuchsin and were placed over a beaker of water on hot plate; the 
preparations were allowed to steam for 5 minutes. Then slides were 
washed with tap water and decolorized with 3% acid alcohol for 2-3 
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minutes and washed again with tap water. Finally, methylene blue was 
added for 30 seconds as counter stain and the smears were then examined 
under oil immersion lens (x100) for presence of AFB.   
 
2.6 medium for isolation:( Lowenstein Jensen medium) 
Components          (g/l) 
Potassium dihydrogen phosphate anhydrous           2.40g 
Magnesium sulphate                                                 0.24g 
Magnesium citrate               0.60g   
L-Asparagine                                                            3.60g 
Glycerol                                                                    12 ml 
Distilled water                                                           600 ml 
 
Preparation: Lowenstein-Jensen medium was prepared as described by      
the International Union Against Tuberculosis and Lung Disease (IUATLD) 
as follows: all the solid ingredients above were added at one time and 
dissolved in distilled water and then autoclaved for 15 minutes at 121°C, 
cooled at room temperature and then 600 ml of this buffer were mixed with 
1000 ml sterile whole-egg homogenate containing 20 ml 1% malachite 
green to give a homogenous mixture. Then 10 ml of the mixture were 
dispensed into sterile glass universal bottles, and inspissated in a slant 
position at 85 °C for 45 minute. 
 
2.7 Culture  method 
Decontamination and concentration of sputum  
Reagents: 
HCl (IN  )    8.3 ml  
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D. W.                 91.7 ml  
NaOH (IN)                                                           4g/100ml  
 
Phenol red                                                            1g 
D. W.                 50 ml  
 
Procedure: The sputum was aseptically transferred into sterile 50 ml 
conical tube, equal volume of NaOH was added, then vortexed and kept at 
room temperature for 20 minutes. The sputum was neutralized with HCl, 
which was added drop by drop until the colour changed (Petroff, 1915).  
 
Inoculation onto Lowenstein-Jensen (L. J.) medium 
    Two tubes of L. J. medium were inoculated with 4 drop Pasteur pipette of 
the neutralized sputum sample. One of the two tubes contained glycerol 
while the other one contained pyruvic acid to isolate M. tuberculosis and 
M. bovis   (Mackie ad McCartney, 1996 ). Inoculated tubes were incubated 
aerobically at 37°C for up to 8 weeks before being discarded. Growth was 
monitored daily during the first week to observe the presence of rapidly 
growring mycobacteria and nocardiae if present, which can show growth 
within 7 days, and then the growth was observed weekly up to the 8th 
week. Characteristics of different colony types found were observed and 
recorded and smears for microscopy were made. Enough growth of M. 
tuberuclosis complex members mostly appeared after 6 weeks.  
 
Growth rate 
The organism was denoted as rapid-grower if it produced visible colonies 
on subculture within 5 days post incubation (usually after 2-3 days) and as 
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slow grower if it produced visible colonies on subculture after 2-6 weeks 
post inoculation (Patrick et al., 2000).   
  
     Purification and preservation of Mycobacterium spp 
     Purification was done by repeated sub-culturing of a part of typical and 
well-isolated colony on L J. medium. Pure isolates were maintained in 
slants of L.J. medium at 4°C and also kept in sterile 20% glycerol as 
described by Wellington and Williams (1978). Moreover, heavy biomass 
(3-4 loops) from young cultures was transfered into sterile cryotubes 
containing 1% skimmed milk. The cell suspension was kept in a deep 
freezer at-70 °C. 
 
     2. 8 Biochemical testing 
   Selected biochemical tests were performed for the identification of the 
isolates. All tests were done according to Mackie and McCartney (1996).  
 
Preparation of mycobacterial fresh solid culture 
 
     One milliliter of sterile distilled water and 5-7 glass beads (3 mm in 
diameter) were put in a sterile screw-capped bottle. A loopful of solid 
growth was transferred to the bottle and the mixture was vortexed for 10 
seconds. With a sterile Pasteur pipte 2 drops of the suspension were added 
to a slope of LJ medium.   
 
2.8.1 Catalase test 
Reagents 
Solution 1 
     Na2HPO4 9.47g 
 45
     Distilled water 1000ml  
    Solution 2 
     KH2PO4 9.07g 
     Distilled water 1000ml  
     Tween 80, 10% 
     Tween 80 10ml 
     Distilled water 90ml  
Solution 1&2 were mixed to provide an 0.067 M phosphate buffer.  
A solution of equal parts of 10% Tween 80 and 30% hydrogen peroxide 
were mixed immediately before use. 
 
Procedure: It is a semi quantitative method, performed as described by 
Betty, Daniel and Alice (1998).  Aseptically, 0.5 ml of 0.06 M phosphate 
buffer was added in a test tube, then several loopfulls of solid culture from 
14 days-old culture were transferred into buffer solution. Then the tube 
was incubated in water bath at 68°C for 20 minutes. After 20 minutes the 
tubes were cooled at room temperature. Then 0.5 ml of freshly prepared 
tween-peroxide mixture in a test tube was added and the cap was replaced 
and left loosely. A column of foam was formed if the catalase test is 
positive, the height of the column was measured; the results were 
interpreted according to (IUATLD, 1998) as follows:        
     Less than 31 mm of foam = Low or no catalase activity                 
     Between 31 and 45 mm of foam = Inconclusive result                               
     More than 45 mm of foam = High catalase activity  
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2.8.2 Nitrate reduction test 
Reagents 
Sodium nitrate substrate in buffer: 
Solution 1 
KH2PO4 3.02g 
Distilled water                                                   1000ml  
Solution 2   
Na2HPO4 3.16g 
Distilled water  1000ml  
     Complete sodium nitrate substrate buffer: 
NaNO3  0.85g 
Distilled water 1000ml 
     Hydrochloric acid solution: 
Concentrated HCL 10ml 
Distilled water 10ml  
     Sulfanilamide solution, 0.2% 
Sulfanilamide  0.2g 
Distilled water 100ml 
     N-naphthylethylene- diamine solution, 0.1%: 
N-naphthylethylene- diamine solution 0.1g 
Distilled water                                                  100ml 
 
Procedure: Nitrate reduction test was done according to Betty et al. 
(1998). In a screw–capped tube 0.2 ml of sterile saline was placed, and 
then 2 loopful of a 4-weeks old solid culture were emulsified in the saline. 
Then 2 ml of NaNO3 were added, and the tube was well shaked and 
incubated upright at 37°C in a water bath for 3 hours. One drop of diluted 
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HCl was added and the tube was shaked well, then 2 drops of 0.2% of 
sulfanilamide and 2 drops of 1% naphthylethylene-diamine were added 
and the mixture was examined immediately for a pink to red color, as a 
positive result and compared to a standard color. If no color,  the result was 
taken as negative.   
 
2.8.3 Sensitivity to para-nitrobenzoic Acid (PNB)  
L .J medium slope with PNB 
PNB 0.2g 
Distilled water  15ml 
NaOH (1 mole/1) 2ml  
 
Procedure: The test was done according to Mackie and McCartney (1996). 
A loopful of fresh solid culture was inoculated onto a slope of LJ medium 
containing 500 mg/L PNB and then incubated at 37°C for 4 weeks. The 
presence of growth indicated that the organism was resistant to PNB and 
the result was considered positive.  
 
2.9 Molecular identification (Polymerase chain reaction)  
   A polymerase chain reaction method was used to confirm the isolation and 
identification results (Eisenach et al., 1990)  
DNA extraction from cultures 
 A loopful culture of each strain was suspended in 500 µl of distilled water, 
inactivated at 80°C for 10 min and pelleted by centrifugation (13000 r. p. 
m for 15 min). The pellet was resuspended in 100 µl of distilled water, 
mixed by vortexing for 2 min and centrifuged as before.  Two microlitter 
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of the supernatant were used as template for PCR amplification ( Kirsi et 
al., 2003). 
 
Primers of insertion sequence IS6110  
Amplification of the insertion sequence IS6110 (123 bp) (Eisenach et al., 
1990) was performed with a set of primers having the following sequence:  
(CCTGCGAGCGTAGGCGTCGG)  and 
(CTCGTCCAGCGCCGCTTCGG) 
Preparation of PCR mixture    
A master mix of reagents of 25 µl was used, which contained:  
2.5 µl PCR buffer (QIAGEN), 2.0 µ dNTP mixture (10mM) (Roche), 1.0 
µl of each primer (25µM) (Biotech), 0.12 µl Taq polymerase (5U/µl) 
(Fermentas), 16.38 µl distilled water and 2.0 µl template DNA. 
The chromosomal DNA of M. tuberculosis strain H37Rv (provided by 
National Reference Laboratory) was used as a positive control. The 
negative control contained all the reagents except the template DNA.   
 PCR amplification 
The amplification was done using a thermal cycler from Biometra 
(Germany). A PCR round was conducted with an initial 5-min denaturation 
step at 95°C coupled to a repeating cycle of denaturation (I-minute at 
95°C), annealing (1 minute at 65°C) and extension (2 min at 72°C) for 35 
cycles, followed by a 10-min final extension step at 72°C.  
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Preparation of agarose gel 
One and half gram agrose (Amersham, UK) were dissolved by boiling in 
100 ml 1xTBE (Tris Boric acid EDTA). Then 5 µl of ethidium bromide 
were added before pouring the liquid agrose gel into the gel casting tray 
which was equiped with suitable comb and its open sides were closed and 
left to solidify. After solidification, the comb was gently removed and the 
closure from the open sides was removed. 
   Product detection  
The gel casting tray was put in the electrophoresis tank, flooded with TBE 
buffer as just to cover the gel surface. Seven microlitter of the PCR 
product from each sample were mixed with 3 µl of loading buffer and then 
the mixture was electrophoresed. Three microlitter of DNA ladder 
(marker) were mixed with 3µl loading buffer and were added in each run. 
The gel electrophoresis apparatus was connected to a power pack 
(Biometra, Germany). The electrophoresis was carried at 85 V for 30 
minutes. After electrophoresis period the gel tray was removed from the 
EP apparatus and the buffer was discarded. Then the gel was visualized by 
UV transilluminator (Biometra, Germany). The molecular size of the 
product was estimated by comparing the migration distances with those of 
a 100-bp DNA ladder. 
2.10 Drug susceptibility testing     
Preparation of antituberculosis-drug media 
 
Isoniazid      20.0mg 
Distilled water     40.0 ml  
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Rifampicin      80.0mg 
Methanol      5.0 ml  
Streptomycin     4.0mg 
Distilled water     50.0 ml  
Ethambutol              20.0mg  
Distilled water           100.0 ml (200.0mg/ml) 
 
Lowenstein Jensen proportion method 
Susceptibility testing was performed by LJ proportion method which was   
described by IUATLD (1998). Two MDR strains and 4 mono-resistant 
strains to rifampicin, ethambutol, streptomycin and isoniazid were used in 
each new batch of the medium. Two hundred isolates were tested against 
four antituberculosis agents, which were RIF, INH, STM and EMB. Fresh 
growth of the test organism on Lowenstein Jensen medium was used as the 
source of inoculum. Sufficient number of colonies was picked up to make 
a suspension equivalent to McFarland standard 1 (original suspension). 
The standard strain M. tuberculosis, H37Rv was used to test each batch of 
the medium. Two dilutions were made from the original suspension, 10-2  
and 10-4 using the calibrated inoculating loop and sterile glass bottles 
containing 1 ml of distilled water. One slope of control medium and two 
slopes of each drug containing medium were inoculated with a loopful 
(0.01 ml) of each dilution. The bottles were incubated at 37°C for 6 weeks. 
After the incubation period, presence of resistant bacilli was determined by 
expressing the resistant portion as a percentage of the total population 
used. 
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CHAPTER THREE 
RESULTS 
3.1   Epidemiological Findings  
3. 1. 1   Gender 
          Among the study population (329 patients), who showed AFB and had 
pulmonary infection, 241 (73.3%) were found to be males, while 88 
(26.7%) were females (Fig. 1). 
 
         3. 1. 2   Age Groups 
  
      The bulk of the patients (213, 64.7%) was found in the age range (21-40 
years). While, the extremities (0-10 years) and >60 years were the least 
affected, 3 and 8 patients, respectively (Table VI and (Fig. 2). 
 
Table VI: Distribution of patients according to age 
 
Age group Number of patients Percentage from total patients 
0-10 3 0.9% 
11-20 32 9.7% 
21-30 107 32.5% 
31-40 106 32.2% 
41-50 57 17.3% 
51-60 16 4.9% 
>60 8 2.4% 
Total 329 100% 
3.1.3 Occupation  
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       It was found that out of the whole study population, 116 (35.3%) were 
labors, 69 (21%) were individuals marginal, 56 (17%) were house wives, 
47 (14%) were students, 6 (1.8%) were officers, 8 (2.4%) were farmers, 
one (0.3%) was a teacher and 26 (8%) were unemployed people (Fig. 3)  
 
 
26.7%
73.3%male
female
 
 
       Fig. 1.  Distribution of patients with suspected pulmonary     
                    tuberculosis according to gender. 
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        Fig. 2. Correlation between number of patients and age groups 
 
 
 
 
 
 
 
 
 54
 
17%
8%
35.3%
21%
14%
2.4%
1.8%
Labors 
Business
persons
House wives
Students
Officers
Farmers
Unemployed
 
 
                          Fig. 3. Occupation of study populations      
 
 
3.1.4   Analysis of patients’ number according to their tribes (possible         
            origins)  
 
       According to the patients’ data collected through a questionnaire form 
(Appendix), a total of 47 tribes were included in this study. People of 
Deinka tribe were found to be the first group under risk (20%), followed 
by Nuba (17%), Fur (10%), Gaalieen (6%), Gawamaa (5%) and Fallata 
tribe (5%). People from other tribes were of low numbers;   they were 
mainly Noier, Shaigia, Rofaa, Hassania and Hawaweer (Fig. 4). The 
number of patients according to tribe indicated that the people from 
western Sudan are mostly affected, followed by people from southern 
Sudan.    
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            Fig.4. Percentages of patients according to their tribes 
 
3.1.5   Treatment status 
        The majority of the patients, 218 (66.3%) were new cases, followed by 
previously treated cases, 62 (18.8%), relapses, 32 (9.7%) and treatment 
failures, 17 (5.0%).  (Fig. 5).   
 
66.3%18.8%
9.7% 5%
new cases
previously treated
replase
treatment failure
 
 
     Fig.  5. Different treatment statuses among patients of    
                  the study 
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3.2 Isolation and identification 
3.2.1 Isolation  
From the collected 329 sputum samples, 294 (89.4%) showed MTC-like 
colonies, 6 (1.8%) were considered rapidly growing mycobateria, 10 
(3.0%) revealed growth similar to Nocardia spp., 6 (1.8%) specimens 
showed growth but due to contamination, colonies of AFB were not 
obtained, 13 (4%) samples showed no growth. and the MTC-like colonies 
were confirmed by some of their phenotypic and genotypic characteristics 
as shown below.  Isolation results are summarized in Fig. 6.  
 
89%
4%1.8%3%
1.8%
M. tuberculosis NO growth Rapid growers of mycobacteria Nocardia spp Purification failure
 
Fig. 6    The percentage of M. tuberculosis and other     
                      organisms in AFB positive samples 
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3.2.2 Growth rate  
The growth rate of the isolates ranged between 3 days and 5 weeks. Most 
of the isolates showed visible growth after 2 weeks. Six out of the 329 
isolates showed visible colonies in 3 days and were identified as rapid 
growers of mycobacteria, while the growth rate of 294 isolates ranged 
between 2 to 5 weeks and they were identified as slow growers and 
considered to belong to MTC species. 
3.2.3 Ziehl-Neelsen staining:  
Smears from suspected MTC, rapid growers of mycobacateria and 
Nocardia species were all found positive for AFB. 
3.2.4 Cultural characteristics 
Cultural properties of all isolates of Mycobacterium tuberculosis complex 
on Lowenstein Jensen medium at 37 ºC were almost the same and all 
colonies were found dry, rough and cream (buff) coloured (Fig. 7). 
3.2.5 Biochemical tests: 
Out of 294 isolates of MTC organisms, 214 (72.8%) were positive for 
para-nitrobenzoic acid (PNB); 223 (75.8%) were positive for nitrate 
reduction (Fig. 8) and 278 (94.5%) isolates were catalase negative at 68°C 
(Table VII). 
Table VII. Results of biochemical tests 
Biochemical test  Number of  positive 
isolates  
Percentage from total 
isolates  
Nitrate reduction 223 75.8% 
Catalase (68°C) 278 94.5% 
PNB 214 72.8% 
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Fig. 7    Growth of Mycobacterium tuberculosis on Lowenstein  
           Jensen medium showing typical cream (buff)-coloured   
            rough colonies  against the green egg-based medium. 
 59
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fi
g.
 8
 N
itr
at
e 
re
du
ct
io
n 
te
st
 f
or
 M
yc
ob
ac
te
riu
m
 t
ub
er
cu
lo
si
s 
co
m
pl
ex
 o
rg
an
is
m
s 
Fr
om
 le
ft 
to
 ri
gh
t, 
de
ep
 p
ur
pl
e 
=4
+,
 p
ur
pl
e 
=3
+,
 c
le
ar
 p
ur
pl
e 
=2
+,
 fa
in
t p
ur
pl
e 
=1
+,
 n
o 
co
lo
r =
ne
ga
tiv
e 
re
ac
tio
n.
 
 60
 3.2.6 Polymerase chain reaction (PCR) 
 3.2.6.1 Amplification of the IS6110 target gene 
Hundred Mycobacterium tuberculosis complex isolates and one 
Mycobacterium tuberculosis reference strain (H37RV) from the National 
Tuberculosis Reference Lab were subjected to conventional PCR. All 
isolates showed a band that was typical in size (123bp) to the target gene 
(1S6110) as indicated by the standard DNA marker (Fig. 9). The PCR was 
not performed for any of the rapidly growing acid-fast bacilli. 
 
 
 
 
 
 
                               M    P    N    4    5    6     7    8   9    10   11 
 
 
 
 
 
 
 
 
 
 
 
 
123bp 
 
 
  Fig.  9.  Example of PCR result. Lane M: marker, Lane P:     
              positive control, lane N: negative control and lanes 4-11:  
              clinical isolates.      
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 3.3 Drug susceptibility test                                                                
        Two hundred isolates were subjected to drug susceptibility test using the 
proportion method. Thirty-five (17.5%) of the  isolates showed growth in 
INH-, 31 (15.5%) of the  isolates showed growth in RIF-, 43 (21.5%) 
isolates showed growth in STM- and 24 (12%) showed growth in EMB -
containing media. Twelve (6%) isolates showed growth in INH and RIF 
and 9 (4.5%) isolates were resistant to the four drugs. In total, 5 (2.5%) 
isolates were resistant to different combinations of three drugs,  133 (66.5 
%) isolates were either mono or multi-drug resistant and 67(33.5%) were 
sensitive for the four drugs as shown in Table VIII and Fig. 10.         
Table VIII: Results of drug resistance 
Drug Number %from tested isolates   
INH 35 17.5% 
RIF 31 15.5% 
STM 43 21.5% 
EMB 24 12% 
Total 133 66.5 
INH+RIF 12 6% 
Combinations of three drugs 5 2.5% 
INH+ RIF+ STM+ ETM 9 4.5% 
Total 26 13% 
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                        Fig.  10.  Resistance of MTC isolates to tuberculosis  
                                        drugs 
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CHAPTER FOUR 
DISCUSSION 
According to the Federal Ministry of Health (FMOH) report 1996 
(Elsoney, 2000), tuberculosis is considered as a leading cause of health 
service utilization in the ambulatory service, ranking 4. The most frequent 
reason for hospital admission, constituting 11.6% of all cases admitted in 
hospitals, and the most frequent cause of hospital deaths, constituting 16% 
of all patients who died in hospitals. 
 
Multi-drug resistance tuberculosis becomes a major problem that increases 
day by day and its prevalence is still unknown in Sudan and some other 
countries. So, new drugs are required for treating multi-drug resistance.  
The aim of the present study is to isolate and identify M. tuberculosis 
complex organisms to determine the prevalence of multi-drug resistance 
among patients with pulmonary tuberculosis in Khartoum State and to 
evaluate the usefulness of PCR as confirmatory test for detection of M. 
tuberculosis complex.  
 
All patients included in this study were smear positive using ZN stain. 
Because culturing technique is required for definitive diagnosis of TB 
(Bahrmmad et al., 1996), all the sputum samples (329) were cultured on 
L.J medium . Out of 329 sputum samples, 294 (89.4%) isolates showed 
typical growth of M. tuberculosis and 10 (3.0%) samples showed the 
appearance of   Nocardia and 6 (1.8%) were rapidly growing 
mycobacteria. This result showed that culture method may be more 
specific than the smear method which can not differentiate between M. 
tuberculosis, MOTT and Nocardia. Similarly, Hamid et al. (2001) reported 
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that out of 400 sputum samples taken from patients suffering from 
pulmonary infection, 8 (2%) samples identified as Nocardia. Culture is  
actually reported as much more sensitive than microscopy (Colebunders 
and Bastian, 2000).  
 
From the epidemiological findings in this study, it was found that the 
number of pulmonary TB-infected males was significantly higher than that 
of the females, 72.3% versus 27.7%. A similar result was reported by El 
Eragi (2004), who found that 66.7% of cases were males and 33.3% were 
females. This finding is also in accordance with that of Bellamy et al. 
(2002), who said that an X chromosome susceptibility gene contributes to 
the high susceptibility of males to TB than females as observed in many 
different populations. The gene in the X chromosome is becomes dominant 
when joined with the Y chromosome and a recessive one when joined with 
the X chromosome. Moreover, according to the job type, males are more 
exposed to sources of infection than females.       
        
  Regarding the correlation between the age of patients and infection rate, it 
was found that young patients between 21 and 40 years were the most 
affected (64.7%). A similar result was obtained by EL Eragi (2004), who 
found that patients with ages between 11-40 years were at the most risk. 
Also, Murray, Styblo and Rouillon (1990) mentioned that almost 80% of 
TB patients were living in developing countries with an age less than 50 
years, and in contrast, in the developed countries most cases were over 50 
years. This can be attributed to the fact that this range of age represents the 
productive age group, thus, the manual effort in addition to the poverty 
which is reflected the malnutrition and poor living conditions, are the 
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predisposing factors. A confirmation of this postulate can be retrieved from 
the fact that in this study the group with highest infection rate was the 
labors’group. 
  
The current  study showed that TB is distributed among different      
occupations with high prevalence in labourers’ category (35.3%), followed 
by those who are engaged in small marginal private jobs (21%), house 
wives' (17%), students (14%), officers (1.8%), farmers (2.4%), teachers 
(0.3%)  and unemployed people (8%). This finding completely agrees with 
the statement that economic status play a major role in TB morbidity, in 
addition, there are many other factors such as overcrowding of poor and 
ill-nourished people, racial differences and in availability of health care 
(Lowel, 1976).   
 
The ethnic study revealed that TB infection is distributed among different 
tribes with different rates. As most patients were from outside Khartoum 
State; ethnic study was undertaken to correlate between patients and their 
geographical areas. Patients from Deinka tribe costituted 20% of cases 
followed by Nuba (16%) and Fur 9%, while patients from other tribes were 
fewer in number. Total number of patients from tribes of Western Sudan 
and those tribes of  Southern Sudan were the highest. This outcome could 
be attributed to the poor economic and health status in these areas. A 
nearly similar result was reported by EL Eragi (2004), who found that most 
cases were from economically poor areas, mainly from Deinka tribe 
(12.9%), Gaalieen (12.2%) and Nuba (10.9%). Genetic and race factors 
should be considered, since there are many reports discussing the 
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relationship between the genetic factors and TB infection (Stead et al., 
1990; Abel and Casanova, 2000).  
 
All 294 isolates of M. tuberculosis complex when subjected to Catalase, 
Nitrate and PNB testing gave results in range according to (IUATLD, 
1998). 
 
     One hundred of the isolates MTC were subjected to conventional PCR 
targeting IS6110 gene which is specific for MTC. A clear band with 
similar size as the targeted gene was observed in the gel for all of the 
isolates. This finding confirmed the isolation result. PCR has been used for 
detection of M. tuberculosis complex, directly in the sputum samples 
(Shah et al., 1995) or after isolation (Shinnick and Good 1995), with high 
degree of sensitivity and specificity.   
 
     The result of antibiotic susceptibility testing revealed that only 33.5% of 
the isolates were sensitive to the four drugs used (INH, RIF, STM, and 
EMB). The rest isolates (66.5%) were eiher resistant to one (mono-drug 
resistance) or more than one drug (multi-drug resistance). Thirty five  
isolates (17.5%) were resistant to INH, 31 (15.5%) to RIF, 43 (21.5%) to 
STM and 24 (12%) to EMB. MDR was shown by 26 (13%) of the isolates, 
12 (6%) of which were resistant to INH and RIF, 5 (2.5%) to different 
combinations of three drugs and 9 (4.5%) to the four drugs. 
 
     Sharaf-el-din et al. (2000) reported 12% resistance to INH (KatG gene), 
8% to RIF (rpoB gene), 30% to STM (rpsl gene ) and 4% to EMB (embB 
gene). These percentages of resistance are lower that those found in our 
study for the four drugs except STM and they are in accordance with their 
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ranking order; i.e. the highest resistance was against STR followed by 
INH, RIF and EMB in both studies. Lesser percentage of resistance to RIF 
(8.3%) was also reported by EL-Eragi (2004).  Resistance to RIF was 
observed in 3.9% of different types of cases, but in 9.0% of patients who 
had been previously treated for tuberculosis, (Tsukamura, 1972). 
Resistance to rifampicin is increasing rapidly as a result of its widespread 
use. Rifampicin-resistant tuberculosis, often observed in conjunction with 
isoniazid resistance, leads to a longer treatment period and significantly 
poorer chemo-therapeutic outcomes (Mitchison.1985).  
 
In general, the differences between the findings of  our study and the 
previous studies may be due to the relative small sample size used in the 
previous studies, different methods of resistance determination or new 
emergence of increasing resistance.   
 
Conclusion 
This study confirmed the presence of tuberculosis in Khartoum State; all 
age groups, occupations and both sexes were found affected with different 
rates. The age between 11-40 years, male patients and people from poor 
economic and health status were at the highest risk. 
 
   The specificity of smear method of diagnosis was only 89.4% compared to 
isolation method which was confirmed by PCR.  PCR assay was 100% in 
agreement with isolation result of M. tuberculosis and simple to perform.  
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The drug-sensitivity testing results revealed increased resistance to the four 
drugs used, especially RIF and INH which are the corner stone for the 
treatment of tuberculosis, when compared to the previous studies. 
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Recommendations 
 
(1) Due to the fact that culture method for tuberculosis identification is 
more sensitive and found in this study more specific than smear 
method, it is highly recommended to always culture the sputum 
samples beside the smear method. A study to isolate the bacteria from 
AFB-negative sputum smears to determine the sensitivity of the smear 
method is also recommended.   
(2) Due to the increased resistance obtained in this study and the 
importance of RIF in treatment and control of the tuberculosis, early 
diagnosis and detection of RIF-resistant strains is important.  
(3) A study to compare between resistant gene detection by PCR and the 
conventional method used in this study is suggested. This may reveal 
higher detection rate by the conventional method than the molecular 
one and necessitate its usage. 
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